0
Sophiris Bio Inc. Banner Image

Sophiris Bio Inc. has reached its limit for free report views

Work for Sophiris Bio Inc.? Upgrade Your Profile and unlock all your annual reports.

Sophiris Bio Inc.

  • Ticker SPHS
    Exchange NASDAQ More
  • Industry Drugs - Generic More
  • Sector Healthcare More
Sophiris Bio Inc. Logo Image
  • 1-10 Employees
  • Based in La Jolla, California
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). TopsalysinMore is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.
Sophiris Bio Inc.

Most Recent Annual Report

Sophiris Bio Inc. MOST RECENT 2018 Annual Report and Form 10K

Report Locked. Sophiris Bio Inc. has reached its limit for free report views.

Sophiris Bio Inc. does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports